Integrated Diagnostics Holdings PLC Biolab to operate testing stations in QAIA (0342J)
18 Agosto 2021 - 4:04AM
UK Regulatory
TIDMIDHC
RNS Number : 0342J
Integrated Diagnostics Holdings PLC
18 August 2021
Biolab, IDH's Jordanian subsidiary, selected as preferred bidder
to operate testing stations in Amman's Queen Alia International
Airport
18 August 2021
(Cairo and London) - Integrated Diagnostics Holdings ("IDH,"
"the Company" or "the Group"), a leading consumer healthcare
company with operations in Egypt, Jordan, Sudan, and Nigeria,
announces that Biolab, IDH's Jordanian subsidiary, has been
selected as the preferred bidder by Airport International Group,
the operator of Amman's Queen Alia International Airport (QAIA), to
operate testing stations in QAIA's departure and arrival areas
primarily dedicated to PCR testing for Covid-19.
The main focus of the testing stations will be to offer PCR
testing for Covid-19 to passengers arriving in Jordan, as well as
additional diagnostic tests to patients including rapid PCR testing
for Covid-19 for departing passengers and other, more generic
diagnostic tests. The agreement came into effect on 1 August
2021.
Commenting on the partnership, Dr. Amid Abdelnour, Biolab's
founder and CEO, said: "We are proud to have been selected as the
preferred bidder by Airport International Group which will enable
Biolab to continue playing a frontline role in the country's fight
against the pandemic. In parallel, this will allow us to expand our
patient base and reach across new segments of the population in
turn driving further growth across our operations. This is also a
testament to the strong reputation for high quality and
affordability offered by Biolab, which in the past two decades has
grown to become a household name in Jordan's diagnostics
industry."
Nicolas Claude, CEO of Airport International Group, commented:
"We are pleased to be partnering with Biolab, which is a reputable
Jordanian diagnostic tests provider. As the aviation industry works
to recover from the severe repercussions of the Covid-19 pandemic,
presenting passengers with access to reliable, internationally
accredited PCR testing for the coronavirus is vital. By providing
testing stations at both Arrivals and Departures, we are actively
prioritising the health and safety of our passengers and employees,
whilst maintaining a positive travel experience and bolstering
traffic via Queen Alia International Airport."
IDH CEO Dr. Hend El Sherbini, added: "I am delighted with
Biolab's ability to secure this landmark partnership, which is only
the latest in a series of agreements signed by IDH over the last
twelve months to offer Covid-19-related tests to travellers. This
is a necessary aspect to safeguard the health of passengers and
crew members while supporting a return to regular international
travel across the region. Looking ahead, our main priority across
both Egypt and Jordan remains helping local authorities combat the
spread of Covid-19, and in the coming months we will look for new
opportunities to offer our Covid-19-related services to a growing
number of patients across both countries."
Established in 2001 by Dr. Amid Abdelnour and acquired by IDH in
2011, Biolab currently operates 20 branches across the country
offering a complete range of laboratory and diagnostic services to
more than half a million patients each year. Since the start of the
Covid-19 pandemic, Biolab has performed more than 600 thousand PCR
and Antibody tests, playing an important role in combatting the
spread of the virus in Jordan. In 2020, the Group's Jordanian
operations were the second largest contributor to IDH's
consolidated revenue with a share of 15.4% up from the 11.5%
contribution made in 2019. Queen Alia International Airport is
Jordan's main and largest airport, and in just the first six months
of 2021 it welcomed over 1.2 million passengers.
-Ends-
About Integrated Diagnostics Holdings (IDH)
IDH is a leading consumer healthcare company in the Middle East
and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The
Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar
in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar
Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record
for quality and safety has earned the Company a trusted reputation,
as well as internationally recognised accreditations for its
portfolio of over 2,000 diagnostics tests. From its base of 483
branches as of 31 March 2021, IDH will continue to add laboratories
through a Hub, Spoke and Spike business model that provides a
scalable platform for efficient expansion. Beyond organic growth,
the Group's expansion plans include acquisitions in new Middle
Eastern, African, and Asian markets where its model is well-suited
to capitalise on similar healthcare and consumer trends and capture
a significant share of fragmented markets. IDH has been a
Jersey-registered entity with a Standard Listing on the Main Market
of the London Stock Exchange (ticker: IDHC) since May 2015 with a
secondary listing on the EGX since May 2021 (ticker: IDHC.CA).
Learn more at idhcorp.com .
The person responsible for arranging the release of this
announcement is Nancy Fahmy, Investor Relations Director at
IDH.
Contact
Nancy Fahmy
Investor Relations Director
T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 |
nancy.fahmy@idhcorp.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDDKFBKCBKKNFD
(END) Dow Jones Newswires
August 18, 2021 05:04 ET (09:04 GMT)
Integrated Diagnostics (LSE:IDHC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Integrated Diagnostics (LSE:IDHC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024